CLEMIZOLE HYDROCHLORIDE

( DrugBank: Clemizole / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
140	ドラベ症候群	3

140. ドラベ症候群

臨床試験数 : 116 / 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003425-30-ES (EUCTR)	27/07/2022	23/03/2022	A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (ClemizoleHCl) ...	A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (ClemizoleHCl) ...	Dravet Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: EPX-100 (Clemizole Hydrochloride) Product Code: EPX-100 INN or Proposed INN: CLEMIZOLE H ...	Epygenix Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	74	Phase 2	United States;Canada;Spain;United Kingdom
2	NCT04462770 (ClinicalTrials.gov)	September 15, 2020	6/7/2020	EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With ...	A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydr ...	Dravet Syndrome	Drug: EPX-100 (Clemizole HCl);Drug: Placebo	Epygenix	NULL	Recruiting	2 Years	N/A	All	100	Phase 2	United States;Canada
3	NCT04069689 (ClinicalTrials.gov)	August 29, 2019	22/8/2019	Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.	A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of ...	Dravet Syndrome	Drug: EPX-100 (Clemizole Hydrochloride);Drug: Placebos	Epygenix	NULL	Completed	18 Years	50 Years	All	24	Phase 1	United States

First Previous1Next Last